Can CloudMD (TSXV:DOC) become a multibagger stock by 2022?

Published on August 26, 2021 10:39 AM EDT

Can CloudMD (TSXV:DOC) become a multibagger stock by 2022? — Image source: Monster Ztudio, Shutterstock.com

Highlights

Digital healthcare company CloudMD (TSXV:DOC) achieved record revenues in the second quarter of 2021.

In Q2 2021, CloudMD closed four acquisitions, namely that of Aspiria, Oncidium, VisionPros, and Rxi.

The global digital healthcare industry’s market value was around US$ 96.5 billion in 2020.

Stocks of CloudMD Software & Services Inc. (TSXV:DOC) jumped about three per cent and closed at C$ 1.87 per share on Wednesday, August 25.

This surge came after the digital healthcare company announced “record” second quarter results for the period ending June 30, 2021.

The Vancouver-based digital healthcare company, CloudMd, enables patients to access medical services through their mobile phones, tablets and laptops. It provides software-as-a-service (SaaS) health technology solutions to clinic in Canada.

After releasing its financial results, CloudMD CEO Dr Essam Hamza said that growth across all the divisions helped the company deliver a robust quarter. He added that CloudMD remains confident to disrupt healthcare industry with a patient-focused approach and achieve significant revenue growth in the next few years.

Also Read: CryptoPunks breaks sales record. Is this the beginning of NFT frenzy?

CloudMD latest financial results

CloudMD’s revenues grew 461 per cent year-over-year (YoY) to C$ 15.7 million in Q2 2021.

In the same quarter, CloudMD’s cash and cash equivalents expanded to C$ 60.9 million, up from C$ 59.7 million as on December 31, 2020.

Its gross profit, on the other hand, surged to C$ 5.6 million in Q2 2021, as compared to C$ 1 million in Q2 2020.

The company closed four acquisitions in the latest quarter, namely that of Aspiria, Oncidium, VisionPros, and Rxi, which is expected to add C$ 96 million of annual revenue.

Seemingly on an expansion mode, CloudMD has set significant financial expectations of annualized revenue run rate, exceeding C$ 140 million, for the third quarter of 2021.

A major acquisition completed by CloudMd was that of Oncidium, which happens to be one of the leading health management companies in the country, with over 500 trusted corporate and public sector clients.

CloudMD (TSXV:DOC) stock performance

DOC shares have returned about nine per cent in the last one week and catapulted by 52 per cent in the last twelve months.

The digital healthcare company's stock jumped by one per cent in the past month, outperforming the Toronto Stock Exchange 300 Composite Index, which dipped by four per cent in the same period.

Also Read: BNS stocks rise as Scotiabank posts $2.5B Q3 profit. Time to buy?

Bottomline

The demand for digital healthcare companies has increased since the outbreak of the coronavirus pandemic as people remained indoors for almost two years.

The global digital healthcare industry’s market value was around US$ 96.5 billion in 2020 and it is expected to grow at a compound annual growth rate of 15.1 per cent from 2021 to 2028, according to a Grand View Research report.

Keeping that projection in mind, firms like CloudMD could record a further spike in their demand in the future.

Raza Naqvi

Author

Raza Naqvi - Financial Journalist
1007 Posts
Raza comes from a hard-news background and is an experienced writer with a demonstrated history of working in reputed organizations like the United Nations, Indian Express, and Hindustan Times. Currently, he is exploring the financial world!...
Shreya Biswas

Editor

Shreya Biswas - Multimedia Journalist
408 Posts
Shreya Biswas is a multimedia journalist with a degree from the Asian College of Journalism. Previously a literature student-turned-political reporter, she now writes on market trends at Kalkine Media. When not chasing deadlines, she enjoys bloggin...

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Incorporated (Kalkine Media), Business Number: 720744275BC0001 and is available for personal and non-commercial use only. The advice given by Kalkine Media through its Content is general information only and it does not take into account the user’s personal investment objectives, financial situation and specific needs. Users should make their own enquiries about any investment and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media is not registered as an investment adviser in Canada under either the provincial or territorial Securities Acts. Some of the Content on this website may be sponsored/non-sponsored, as applicable, however, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used in the Content unless stated otherwise. The images/music that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.